APVO (Aptevo Therapeutics) FFO


APVO Aptevo Therapeutics Inc APVO
29 GF Score
Price $4.55
! 1 Warning Sign
View Full Analysis

What is Aptevo Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

APVO
29GF Score
Aptevo Therapeutics Inc APVO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptevo Therapeutics Business Description

Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score

Get the complete analysis for APVO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.55
Price